Value-Based Care

While limited in some respects, researchers from the Medical University of Vienna have endorsed the European Society for Medical Oncology Magnitude of Clinical Benefit Scale as a useful tool for aiding drug selection in cancer care.
Researchers from the department of radiation oncology at the VU University Medical Center in Amsterdam, the Netherlands, have proposed a novel formula for the optimization of radiosurgery dose for any given lesion volume in patients with brain metastasis.  
In a session at their 21st Annual Meeting in Hollywood, FL, National Comprehensive Cancer Network (NCCN) CEO Robert W Carlson, MD, discussed how NCCN Evidence Blocks stack up against other tools currently available for determining the value of cancer treatments. 
A tool integrating costs associated with common cancer treatments with electronic medical records was beneficial to both physicians and patients, according to results of a study presented at the conference.